In October 2023, Tessellate emerged from stealth, with an initial €8m in seed funding backed by two leading European venture capital firms, BioGeneration Ventures (BGV) and Forbion. Its lead program targets the DNA damage response (DDR) and in particular cancers that depend on Alternative Lengthening of Telomeres (ALT).

The company aims to become a global leader in precision oncology by redefining Synthetic Lethality. While Synthetic Lethality approaches targeting Homology Recombination Deficiency (HRD) have been successfully validated in the clinic by PARP inhibitors, there remains a vast and largely unexplored space in Synthetic Lethality beyond HRD that Tessellate BIO is pioneering.